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Blindness arising from retinal or macular degeneration results in significant social,
health and economic burden. While approved treatments exist for neovascular (‘wet’)
age-related macular degeneration, new therapeutic targets/interventions are needed
for the more prevalent atrophic (‘dry’) form of age-related macular degeneration.
Similarly, in inherited retinal diseases, most patients have no access to an effective
treatment. Although macular and retinal degenerations are genetically and clinically
distinct, common pathological hallmarks can include photoreceptor degeneration,
retinal pigment epithelium atrophy, oxidative stress, hypoxia and defective autophagy.
Here, we evaluated the potential of selective histone deacetylase 6 inhibitors to
preserve retinal morphology or restore vision in zebrafish atp6v0e1−/− and mouse rd10
models. Histone deacetylase 6 inhibitor, tubastatin A-treated atp6v0e1−/− zebrafish
show marked improvement in photoreceptor outer segment area (44.7%, p = 0.027)
and significant improvement in vision (8-fold, p ≤ 0.0001). Tubastatin A-treated
rd10/rd10 retinal explants show a significantly (p = 0.016) increased number of outer-
segment labeled cone photoreceptors. In vitro, ATP6V0E1 regulated HIF-1α activity, but
significant regulation of HIF-1α by histone deacetylase 6 inhibition in the retina was
not detected. Proteomic profiling identified ubiquitin-proteasome, phototransduction,
metabolism and phagosome as pathways, whose altered expression correlated with
histone deacetylase 6 inhibitor mediated restoration of vision.
Keywords: HDAC6 inhibitors, tubastatin A, retinal degenerations, Hif-1α, proteome profiling
Abbreviations: AD, Alzheimer’s disease; AMD, Age-related macular degenerations; BafA, Bafilomycin A1; CMZ, Ciliary
marginal zone; DMSO, Dimethyl sulfoxide; dpf, Days post fertilization; FOV, Field of view; HDAC6i, Histone deacetylase 6
inhibitors; HDACi, Histone deacetylase inhibitors; HDACs, Histone deacetylases; HPT, Hours post treatment; IRD, Inherited
retinal degenerations; MTC, Maximum tolerated concentration; OKR, Optokinetic Response; ONL, Outer nuclear layer; PFA,
Paraformaldehyde; RP, Retinitis pigmentosa; RPE, Retinal pigment epithelium; RPM, Revolutions per minute; RT, Room
temperature; Saccades/min, Saccades/minute; TubA, Tubastatin A; V-ATPases, Vacuolar H+ ATPases.
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INTRODUCTION
Inherited retinal diseases (IRD) and age-related macular
degenerations (AMD) are heterogenous groups of diseases
causing blindness. With a prevalence of 1 in 3000 people affected
worldwide, common forms of IRD include retinitis pigmentosa
(RP), cone/rod dystrophy, Leber congenital amaurosis and
Stargardt disease (Duncan et al., 2018). Variants in over 270
genes can result in monogenic IRD, this heterogeneity makes
clinical diagnosis and prognosis challenging (Daiger et al., 1998).
A significant milestone was the recent regulatory approval
of Luxturna R©, a gene therapy for Leber congenital amaurosis
patients with recessive mutations in RPE65 (Duncan et al., 2018;
Gordon et al., 2019). Neovascular (‘wet’) and atrophic (‘dry’)
AMD have a global prevalence of 170 million. Anti-vascular
endothelial growth factor therapies are approved treatments
for wet-AMD (Hernandez-Zimbron et al., 2018; Holekamp,
2019). However, there is an unmet clinical need for treatments
for dry-AMD (Pennington and DeAngelis, 2016; Hernandez-
Zimbron et al., 2018). Drug-based (e.g., neuroprotectants,
anti-inflammatory, statins, visual cycle inhibitors, complement
inhibitors) clinical trials for IRD and AMD are on-going, albeit
many of the previous ones demonstrated limited success (Waugh
et al., 2018; Sundaramurthi et al., 2019). This highlights that the
vast majority of IRD and dry-AMD patients currently have no
access to an effective treatment.
Histone deacetylases (HDACs) are enzymes that regulate gene
expression through the removal of an acetyl group from histone
and non-histone proteins (de Ruijter et al., 2003). There are
18 mammalian HDACs, classified into four main categories in
accordance to their homology with related proteins in yeast (Xu
et al., 2007; Haberland et al., 2009). Class I comprises of HDACs
1, 2, 3, and 8, they localize to the nucleus and are dependent on
Zn2+ for their activity. Class II are also Zn2+ dependent, and
functional in both the nucleus and cytoplasm. The roles of Class
II HDACs are more tissue-specific, and they are sub-divided into
IIa (HDACs 4, 5, 7, and 9) and IIb (HDACs 6 and 10) (Yang
and Gregoire, 2005). Sirtuins or Class III HDACs (SIRT 1-7) are
NAD+-dependent and are found in the nucleus, cytoplasm or
mitochondria (Park and Kim, 2020). Not much is known about
Class IV, which is made up of only HDAC11. Histone deacetylase
inhibitors (HDACi) are gaining attention as potential therapeutic
agents for various diseases, including cancer, neurodegenerative
diseases and inflammatory diseases (Zhang et al., 2015; Hull et al.,
2016; Eckschlager et al., 2017; Ziemka-Nalecz et al., 2018).
Histone deacetylase inhibitors exert neuroprotective action
in central nervous system diseases e.g., Parkinson’s, Alzheimer’s,
amyotrophic lateral sclerosis and spinal muscular atrophy (Lai
et al., 2017; Janczura et al., 2018; Thomas and D’Mello, 2018).
Preclinical studies show pan-HDAC inhibition to efficiently
restore visual function in zebrafish and mouse models of
inherited blindness (Trifunovic et al., 2016; Daly et al., 2017;
Ratay et al., 2018; Trifunovic et al., 2018). In contrast, in Xenopus
RP models, pan-HDAC inhibition resulted in beneficial or
unfavorable effects depending on the rhodopsin mutation tested
(Vent-Schmidt et al., 2017). Similarly, clinical trials evaluating
pan-HDACi were contradictory, improving visual acuity in some
RP patients while detrimental to vision in others (Clemson et al.,
2011; van Schooneveld et al., 2011; Sisk, 2012; Bhalla et al., 2013;
Iraha et al., 2016; Totan et al., 2017). Due to these controversies,
we investigated if selective inhibitors of the HDAC6 isoform
offer an effective alternative to restore or preserve vision and
retinal morphology.
Unlike other HDACs, HDAC6 is a cytoplasmic protein with
two catalytic domains, which deacetylates non-histone proteins
(Boyault et al., 2007). HDAC6 modulates proteins regulating
numerous cellular pathways including the ubiquitin-proteasome,
autophagy, stress responses (e.g., heat-shock response), redox
signaling, inflammation and intracellular trafficking (Boyault
et al., 2007; Li et al., 2013; Richter-Landsberg and Leyk, 2013;
Simoes-Pires et al., 2013; Ryu et al., 2017). Several studies report
beneficial effects mediated by HDAC6 inhibitors (HDAC6i) in
neurodegenerative diseases (Benoy et al., 2017; Cosenza and
Pozzi, 2018). Selective HDAC6i rectified mitochondrial transport
defects in Charcot-Marie-Tooth disease models, and reduced
hyperphosphorylated tau levels and amyloid-beta accumulation
in Alzheimer’s models in mice (Simoes-Pires et al., 2013; Zhang
et al., 2014; Benoy et al., 2017). The selective HDAC6i, tubastatin
A (TubA), was neuroprotective to photoreceptors subjected
to oxidative stress and restored vision in the atp6v0e1−/−
zebrafish model of inherited blindness (Leyk et al., 2017). This
zebrafish line harbors a mutation in the vacuolar H+ ATPase
(V-ATPase), V0 subunit e1 gene (atp6v0e1), and presents with
retinal degeneration, hypopigmentation, pericardial/abdominal
edema and a deflated swim bladder (Daly et al., 2017). V-ATPases
are ATP-dependent, multi-subunit proton pump complexes that
acidify cellular organelles (e.g., lysosomes, phagosomes and
endosomes) and centrally linked to the process of autophagy
(Pamarthy et al., 2018). Notably, dysregulated autophagy is
reported in models of IRD and AMD (Mitter et al., 2014;
Moreno et al., 2018). Mutations or deficiencies in V-ATPases
and accessory proteins cause frontotemporal lobar degeneration,
Alzheimer’s, a rare form of Parkinson’s, osteopetrosis or
osteoporosis (Lee et al., 2015; Colacurcio and Nixon, 2016;
Duan et al., 2018). In the eye, the V-ATPase accessory subunit
TMEM199 is genetically linked with susceptibility to developing
AMD, suggesting potential roles of other V-ATPase subunits
and accessory subunits in contributing to the pathogenesis of
AMD (Ratnapriya et al., 2019). In RPE lysosomes, the lipofuscin
fluorophore A2-E inhibits the V-ATPase pump which may
contribute to AMD pathogenesis by impairing phagolysosomal
degradation of phagocytosed photoreceptor outer segment
phospholipids (Finnemann et al., 2002; Bergmann et al., 2004).
Impaired function of numerous V-ATPase subunits, atp6v1h,
atp6v1f, atp6v1e1, atp6v0c, and atp6v0d1, and accessory protein,
atp6ap1, results in inherited blindness and retinal degeneration
in zebrafish, and other pre-clinical models (Nuckels et al., 2009;
Kawamura et al., 2010; Shine et al., 2014).
A hallmark of IRD is oxidative damage leading to a
hypoxic environment and stress in the retina (Masuda et al.,
2017; Trachsel-Moncho et al., 2018). Recently, it was reported
that V-ATPase subunit, ATP6V1A1, and accessory proteins,
TMEM199 and CCDC115, regulate HIF-1α levels through
controlling free intracellular iron levels (Miles et al., 2017).
However, an equivalent role for the ATP6V0E1 subunit was
not investigated. Reducing HIF-1α levels has proven to protect
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photoreceptor cells from degeneration thus, providing a potential
therapeutic target for IRD (Vadlapatla et al., 2013; Barben
et al., 2018a; Samardzija et al., 2019). We investigated whether
ATP6V0E1 regulates HIF-1α signaling and whether inhibition of
HDAC6 modulates HIF-1α target genes in the retina.
The goal of the present study was to identify HDAC6
inhibitors that elicits robust neuroprotection in genetic model(s)
of retinal blindness and to understand the molecular mechanism
through which neuroprotection and restoration of vision is
mediated. We show TubA is highly effective in restoring visual
function and is neuroprotective of cone photoreceptor cells
in zebrafish and mice models. TubA regulation of cellular
pathways including phototransduction, metabolism, ubiquitin-
proteasome and phagocytosis correlated with improvement of
cone photoreceptor vision.
METHODOLOGY
Animal Husbandry and Maintenance
Zebrafish
All animal experiments were performed with prior approval
granted by UCD Animal Research Ethics Committee and Health
Products Regulatory Authority (License AE18982/P062 and
AE18982/P134), Ireland. Zebrafish environmental parameters
are reported (dx.doi.org/10.17504/protocols.io.8vshw6e) and
husbandry was carried out in accordance to established
laboratory protocols (Howe et al., 2013). Embryos and larvae
from wildtype (Tübingen) and atp6v0e1−/− knock-out (official
allele designation atp6v0e1UCD6) backgrounds were maintained
on a 14 h light/10 h dark cycle at 28.5◦C in embryo medium
(0.137 M NaCl, 5.5 mM Na2HPO4, 5.4 mM KCl, 1.3 mM CaCl2,
0.44 mM KH2PO4, 1 mM MgSO4 and 4.2 mM NaHCO3, with
conductivity of 1200 µS and pH 7) with methylene blue (Daly
et al., 2017). Adults were maintained in a recirculating water
system at 28◦C under 14 h light/10 h dark cycle and fed daily
with brine shrimp and dry pellet food. Homozygous atp6v0e1−/−
larvae were bred by incrosses of carriers and maintained by
incrosses of carriers and outcrosses of carriers to wildtype fish.
Mice
All animals were handled and maintained following the
ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research (License AE19130). Experiments were approved
by University College Cork Animal Experimentation Ethics
Committee and were performed using both male and female
homozygous rd10 mice (B6.CXB1-Pde6brd10/J). Mice were
supplied by the Biological Services Unit, University College Cork
and were humanely euthanized by cervical dislocation. Mice were
exposed to a 12 h light/12 h dark cycle.
Drug Treatments in Zebrafish Larvae and
rd10 Rodent Explants
Zebrafish Larvae Drug Treatments
Wildtype larvae were treated with increasing drug concentrations
(1–100 µM) of tubacin (Sigma-Aldrich, St. Louis, MO,
United States), ACY-1215 (Ricolinostat; Selleck Chemicals,
Houston, TX, United States), NF2373 (provided by Giuseppe
Campiani) and Fe (III) citrate (Sigma-Aldrich). To determine
the maximum tolerated concentration (MTC), four 3 dpf larvae
were placed in each well of a 48-well plate with either 400 µl
of 0.1% DMSO (dimethyl sulfoxide, vehicle control) or select
concentrations of chosen drugs in duplicate or triplicate until
5 dpf. The MTC was determined based on the given criteria: (1)
an adverse effect was not observed in overall gross morphology
of surviving (> 80% survival rate) larvae and (2) the average
number of OKR saccades was not reduced by> 15% compared to
controls. 12 siblings (atp6v0e1+/+ and atp6v0e1+/− larvae) and
atp6v0e1−/− larvae each were used to test the efficacy of select
HDAC6i at the desired MTC. At 3 dpf, larvae were placed in
60× 15 mm petri dishes and treated with either 10 ml of 100 µM
TubA (Selleck Chemicals), 10 µM Tubacin, 10 µM ACY-1215,
25 µM NF2373 or 100 µM Fe (III) citrate + 100 µM ascorbic
acid (Sigma-Aldrich) + 1 mg/ml lactoferrin (Sigma-Aldrich)
and 0.1% DMSO. All drug solutions were prepared in embryo
medium. Larvae in dishes were placed into a secondary container
and incubated in a 14 h light/10 h dark cycle at 28.5◦C, for 4 h or
between 3 – 8 dpf, with or without changes to drug solution.
Rodent Retinal Explant Culture
Retinal explants were prepared from postnatal day 14 (P14) rd10
mice as described previously (Roche et al., 2017, 2018; Ruiz
Lopez et al., 2017). P14 to P18 explant culture was selected
based on the significantly reduced outer segment length observed
in rd10 retina compared to wildtype retinae from P10 to P15,
without a corresponding significant change in outer nuclear
layer (ONL) thickness (Roche et al., 2017). Therefore, the
selected time frame allows investigation of rescue to rod and
cone outer segment morphology at early stages of degeneration.
Briefly, eyes were enucleated and transferred to a sterile laminar
flow hood. Whole retinae were carefully dissected and placed
photoreceptor-side down without the RPE, on a cell culture insert
in advanced Dulbecco’s modified Eagle’s medium (DMEM)-F12
(Sigma-Aldrich) supplemented with 1% penicillin/streptomycin.
An attached RPE is important for retinal explant cultures from
earlier developmental stages to mature, but in P14 explants the
murine retina has already elaborated outer segments in vivo by
P12 (Pinzon-Duarte et al., 2000; Bassett and Wallace, 2012).
Retinal explants were cultured for 4 days (96 h) in six-well plates
with 1.5 mL media per well/explant, with a media change at
day 3. Explants were exposed to various concentrations of TubA
(200 mM stock solution in DMSO) ranging from 10 to 100 µM.
All explants were exposed to the same volume of DMSO. The
vehicle control was exposed to DMSO alone.
Measure of Visual Function – Optokinetic
Response (OKR) Assay
Optokinetic Response assays were performed as described
previously (Daly et al., 2017). Vehicle and drug treated larvae
were removed from treatment solution and replaced with
embryo medium. Larvae were individually immobilized in 9%
methylcellulose (prepared in embryo medium), in a 60× 15 mm
petri dish. Each larva was placed in the center of the OKR rig and
subjected to rotating black and white stripes (20 vertical, 1 cm
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thick stripes, angle subtended 33.2◦, contrast 99%), rotated at 18
revolutions per minute (RPM), for 30 s in the clockwise and anti-
clockwise direction. Saccadic eye movements produced by the
larva was counted for a total duration of 1 min.
Analysis of Retinal Histology
Light and Electron Microscopy Imaging
Zebrafish larval samples were euthanized in tricaine and
fixed immediately in 4% paraformaldehyde (PFA) and 2.5%
glutaraldehyde prepared in 0.1 M Sorensons’s buffer (pH 7.3)
overnight up to a week at 4◦C. Then samples were post-fixed
with 1% osmium tetraoxide and dehydrated with increasing
concentrations of ethanol. This was followed by incubation
in decreasing concentration of propylene oxide:EPON resin
mixtures. Lastly, samples were embedded in 100% EPON
resin. Samples in resin were polymerized overnight at 60◦C.
500 nM–1 µM thick sections were collected for light microscopy
and 80 nM thick sections for electron microscopy using
Leica EM UC6 microtome (Leica, Wetzlar, Germany). Sections
for light microscopy were mounted on to glass slides and
stained with toluidine blue prior to imaging with Leica DMLB
bright field illumination microscope and a Leica DFC 480
camera (Leica). Sections collected for electron microscopy were
stained with uranyl acetate and lead citrate and imaged with
FEI Tecnai 120 transmission electron microscope (Thermo
Fisher Scientific, Waltham, MA, United States). Three sections,
taken from the central retina per sample, imaged at a
magnification of 2550x were used for the measurement of
total number of photoreceptors and total area of photoreceptor
outer segments. Photoreceptors were counted if both the
outer and inner segments were identifiable. The area of
individual photoreceptor’s outer segment was measured using
ImageJ, by selecting each region of interest and utilizing the
Measurement tool. A total of two individual larvae were analyzed
per sample group.
Immunohistochemistry and Confocal Microscopy
Zebrafish larvae were fixed in 4% PFA overnight at 4◦C. Larvae
were washed with 1 × PBST for 5 min, 3 times. Larvae were
mounted in 1.5% low melting agarose/5% sucrose/1 × PBST
and cryoprotected in 30% sucrose/1 × PBST solution, overnight
at 4◦C. Samples were covered in OCT Compound Tissue-Tek
(Sigma-Aldrich) and flash frozen in liquid nitrogen. 16 µM thick
sections were prepared in the cryotome (Leica) and alternate
sections were collected onto four Superfrost glass slides (Fisher
Scientific, Waltham, MA, United States) and stored at −20◦C.
Sections were dried at 37◦C for 1 h and rehydrated with 1× PBST
for 5 mins. Samples were labeled with primary antibodies, zpr-1
(1:100, ZIRC) or zpr-3 (1:100, ZIRC), for 2 h at room temperature
(RT). Slides were washed with 1 × PBST, 5 times for 7 min
each. Sections were incubated with secondary antibody, Anti
mouse-Alexa Fluor R© 488 Conjugate (1:500, #4408, Cell Signaling
Technology, Danvers, MA, United States) for 1 h at RT. Slides
were washed as before and incubated with DAPI (1:500, Sigma-
Aldrich) for 15 min, RT. Samples were washed and mounted
with Mowiol (Sigma-Aldrich) and stored at 4◦C. All samples
were imaged at a lens magnification of 20x or 63x (with an
additional digital zoom of 3x) using Zeiss LSM 510 laser scanning
confocal microscope. Images were taken in the same session to
ensure identical microscope settings used when imaging across
each treatment groups. Individual cone cells, labeled with zpr-1
staining, were quantified from three sections per sample (N = 3).
The total area of photoreceptor outer segments (labeled with
zpr-3, three sections per sample and N = 3) was measured
using ImageJ, by selecting each region of interest and utilizing
the Measurement tool. Statistical analysis was performed using
unpaired Student’s T test.
Mice retinal whole mounts were fixed in 4% PFA for 30 mins,
at RT. Following washes, retinae to be used for sectioning were
cryoprotected in 15% sucrose in 1 × PBS for 1 h, 20% sucrose
for 1 h, and 30% sucrose overnight, all at 4◦C. Retinae were
submerged and frozen in cryochrome (Thermo Fisher Scientific)
and sectioned on a cryostat (Leica). Sections (10 µm) were
collected on Superfrost glass slides (Fisher Scientific) and stored
at −80◦C. Sections were blocked and permeabilized with 0.1%
Triton X-100 and 5% donkey serum in 1 × PBS for 30 min
and incubated with primary antibody diluted in 5% donkey
serum overnight at 4◦C (Rhodopsin, Thermo Fischer Scientific
#MS-1233, 1:100; Cone Arrestin, Merck Millipore #AB15282,
1:100, Burlington, MA, United States). Retinal whole mounts
were blocked and permeabilized with 4% Triton X-100 and
5% donkey serum in 1 × PBS for 1.5 hrs and incubated with
primary antibody overnight at 4◦C (Rhodopsin, Thermo Fischer
Scientific #MS-1233, 1:100; Cone Arrestin, Merck Millipore
#AB15282, 1:100). Following washes, sections/retinal whole
mounts were incubated with secondary antibody (Alexa Fluor
donkey anti-mouse/rabbit/goat with either a Alexa Fluor R© 488
or a Alexa Fluor R© 594 fluorescent probe; Molecular Probes,
Eugene, OR, United States) and Hoechst 33342 nuclear stain
(1:10,000; Thermo Fischer Scientific) for 1 and 2 h, respectively,
at RT. Eliminating the primary antibody in solution served as a
negative control. Sections/retinal whole mounts were mounted
using Mowiol R© (Sigma-Aldrich) with DABCO R© antifade agent
(Sigma-Aldrich). Retinal sections and whole-mount preparations
were viewed using a Leica DM LB2 microscope with Nikon
Digital Sight DS-U2 camera (Nikon, Tokyo, Japan), using × 10
and × 40 objectives. Images were taken using the software NIS-
Elements version 3.0 (Nikon). All images shown were taken
in the central retina. Numbers of nuclei were counted using
Hoechst 33342. Rods and cones were identified from rhodopsin-
and cone arrestin- positivity, respectively. Fluorescence intensity
measurements were taken using ImageJ software (National
Institutes of Health, Bethesda, MD, United States). Samples were
processed at the same time using the same buffers and antibody
solutions. Identical microscope settings were used when imaging
each preparation across treatment groups, and images were taken
in the same session.
Whole Genome Sequencing
Genomic DNA was isolated from 5 dpf whole larvae using
the DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany),
according to manufacturer’s instructions. A pooled sample
of 20 siblings (atp6v0e1+/+ and atp6v0e1+/− larvae) and
atp6v0e1−/− larvae each were used. Samples were outsourced to
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Novogene Co., Ltd. (Beijing, China) for genome sequencing and
bioinformatic analysis with the following parameters: Illumina
PE150 sequencer with 30x coverage, mapping of sequence reads
with CASAVA software. Integrative Genomics Viewer (IGV)
(Robinson et al., 2011; Thorvaldsdottir et al., 2013) software was
used to analyze sequence of atp6v0e1 gene in Chromosome 14,
for mutation identification.
RNA Isolation
Sixty eyes each were dissected from 3 and 6 days old siblings
(atp6v0e1+/+ and atp6v0e1+/− larvae) and atp6v0e1−/− larvae
treated with either 100 µM TubA or 0.1% DMSO, and RNA was
isolated at two time points, 4 h and 3 days, post treatment. Prior to
dissection, drug treated larvae were washed with embryo medium
thrice, euthanized in tricaine and placed into RNAlater overnight
at 4◦C. Dissected eye tissues were homogenized in Lysis buffer
provided in the mirVanaTM miRNA Isolation Kit (Thermo Fisher
Scientific) with a 26 gauge 3/8II needle/syringe. RNA was isolated
from the homogenized eye tissues using mirVanaTM miRNA
Isolation Kit in accordance to manufacturer’s protocol. Eluted
RNA samples were precipitated with 100% ethanol and 3M
sodium acetate, overnight at −20◦C. Samples were spun down
for 1 hr at 14,000 RPM at 4◦C. The supernatant was removed,
and pellet was washed with 80% ethanol as before. Samples
were dried, pellet was re-dissolved in ultrapure water and stored
at −80◦C till use. Sample purity (RNA integrity number) and
concentration was measured using the Agilent 2100 Bioanalyzer
System (Agilent, Santa Clara, CA, United States).
Quantification of RNA Transcript Levels
Using qRT-PCR
cDNA was synthesized from RNA samples utilizing
PrimeScriptTM RT reagent Kit (Perfect Real Time) (TaKaRa
Bio Inc., Shiga Prefecture, Japan) with random 6-mers and Oligo
dT primers, according to the manufacturer’s protocol. Master
mix containing forward and reverse primers, SYBR Green I
Master Mix, RNAse-free water was prepared on ice and 1 µl of
cDNA template (5 × dilution of stock) added individually in a
384-well plate. QRT-PCR amplifications were carried out with
QuantStudio 7 Flex Real-Time PCR System (Applied Biosystems,
Foster City, CA, United States) with the following cycling
conditions: 50◦C for 2 min, 95◦C for 10 min, 95◦C for 15 s with
40 repeats and 60◦C for 1 min. All reactions were performed with
3 biological and 2 technical repeats. Primers used are hif1aa_For:
GCCACACTTTAGACATGCGC; hif1aa_Rev: GGCTGTGGT
GTGTTTTGGTC; ca9_For: ATCCAGAAGACAGCTCGCAG;
ca9_Rev: TCCCATGCAAAAGTTGTGGTG; slca1a_For: TCGA
AGCTGGCTGAATCCTG; slca1a_Rev: TCGGGGCAATTTCTC
CAACA; vhl_For: TAGCTCAGAGACCCAGCATT; vhl_Rev:
CAGTACATATGCACAGTCCAG; opn1lw2_For: TGATGGC
TCTGAGGT; opn1lw2_Rev: TCCAGTTCTTCCCTCTTGTTC;
gnat2_For: CGTGATCTGAGGTACAGGGC; gnat2_Rev: GCT
ACCCATCTCGTCGTCTG; rx2_For: TCCAGCCCACCTATAC
TGCT; rx2_Rev: ACTGGTTGGCATTGGTAGGG; β-actin_For:
CTTCCTGGGTATGGAATCTTGC and β-actin_Rev: GTGGAA
GGAGCAAGAGAGGTG.
Mass Spectrometry Analysis
Sample Preparation and Mass Spectrometry
Protein was isolated from the eyes of 0.1% DMSO or 100 µM
TubA treated siblings (atp6v0e1+/+ and atp6v0e1+/− larvae)
and atp6v0e1−/− larvae at 6 dpf, using iST Sample Preparation
Kit (mammalian tissue, PREOMICS, Martinsried, Germany)
according to manufacturer’s protocol. Eyes were dissected from
24 to 30 larvae for protein isolation from each treatment group
(N = 3). Samples were analyzed by the Mass Spectrometry
Resource (MSR) in University College Dublin on a Thermo
Scientific Q Exactive mass spectrometer connected to a Dionex
Ultimate 3000 (RSLCnano) chromatography system. Peptides
were separated on C18 home-made column (C18RP Reposil-
Pur, 100 × 0.075 mm × 3 µm) over 150 min at a flow rate
of 250 nL/min with a linear gradient of increasing acetonitrile
from 1% to 27%. The mass spectrometer was operated in data
dependent mode; a high resolution (70,000) MS scan (300–
1600 m/z) was performed to select the twelve most intense
ions and fragmented using high energy C-trap dissociation
for MS/MS analysis.
Data Processing and Bioinformatics
Raw data from the Q-Exactive was processed using MaxQuant
(Cox and Mann, 2008; Tyanova et al., 2016a) (version 1.6.4.0)
incorporating the Andromeda search engine (Cox et al., 2011).
To identify peptides and proteins, MS/MS spectra were matched
against Uniprot Danio rerio database (2018_05) containing
46,933 entries. All searches were performed using the default
setting of MaxQuant, with trypsin as specified enzyme allowing
two missed cleavages and a false discovery rate of 1% on
the peptide and protein level. The database searches were
performed with carbamidomethyl (C) as fixed modification
and acetylation (protein N terminus) and oxidation (M)
as variable modifications. For the generation of label free
quantitative (LFQ) ion intensities for protein profiles, signals of
corresponding peptides in different nano-HPLC MS/MS runs
were matched by MaxQuant in a maximum time window of
1 min (MAXLFQ) (Cox et al., 2014). The Perseus (Tyanova
et al., 2016b) computational platform (version 1.6.2.3) was used
to process MaxQuant results. Data was log transformed. To
examine changes in protein expression using volcano plots,
data was log transformed and missing values were imputed
with values from a normal distribution. Data was normalized
using z-score and visualized using heat maps. In order to
evaluate pathway annotation networks of enriched proteins (t-
test p-value< 0.5) from atp6v0e1−/− + 100 µM TubA compared
with atp6v0e1−/− + 0.1% DMSO or atp6v0e1−/− + 0.1%
DMSO compared with Sibling + 0.1% DMSO, pathway
enrichment analysis was performed using the ClueGo (Bindea
et al., 2009) (v2.5.2) and Cluepedia (Bindea et al., 2013)
(v1.5.2) plugins in Cytoscape (Shannon et al., 2003) (v3.6.1)
with the danio rerio (7955) marker set. The KEGG (Ogata
et al., 1999) functional pathway databases, consisting of 6,004
genes, were used. GO tree levels (min = 3; max = 8)
and GO term restriction (min#genes = 3, min% = 1%)
were set and terms were grouped using a Kappa Score
Threshold of 0.4. The classification was performed by the right
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sided-hypergeometric enrichment test, and its probability value
was corrected by the Benjamini-Hochberg (Adjusted% Term
p-value leq 0.05).
Cell Work on Hypoxia
HeLa HRE-GFPODD cells were maintained in DMEM
(Sigma-Aldrich) supplemented with 10% fetal calf serum
(Sigma-Aldrich) and 100 units/ml penicillin and 100 µg/ml
streptomycin in a 5% CO2 incubator at 37◦C. HeLa HRE-
GFPODD cells were produced as described previously to facilitate
quantitative analysis of Hif-1α activity (Burr et al., 2016). CRISPR
sgRNAs were cloned into lentiviral expression vector pKLV-
U6sgRNA(BbsI)-pGKPuro2ABFP. Cas9 is stably expressed in
the cells using a lentiviral vector (Lenti-CAS9-T2A-Blastocydin)
as described previously (Miles et al., 2017). All sgRNA sequences
used are ATP6V0E1_guide 1: GCGGCGACCATGGCGTATCA,
ATP6V0E1_guide 2: AGTGAGGCCGTGATACGCCA,
ATP6V0E1_guide 3: TCACAATGAGAGGCACAGTG
and PHD2_guide 1: ATGCCGTGCTTGTTCATGCA. The
ATP6V0E1 guides were selected from the Sabatini library and
the specificity and efficiency of all guides were predicted using
the CRISPOR Tool (Table 1) (Park et al., 2017; Concordet
and Haeussler, 2018). HEK293T cells were transfected using
TransIT-293 (Mirus Bio, Madison, WI, United States) following
manufacturer’s protocol. 2 µg DNA [3:2:4 ratio of the relevant
lentiviral transgene vector, pCMVR8.91 (gag/pol) and pMD.G
(VSVG)] was used in 6 well plates with cells at 80% confluency
in 2 ml media. Viral supernatant was harvested after 48 h,
filtered through a 0.45 µM filter and stored at −80◦C. Lentiviral
transduction was performed by adding 500 µl of virus to 2× 105
cells in a 24 well plate made up to 1 ml media. Cell plates
were centrifuged for 1 h at 37◦C at 1,800 rpm immediately
after addition of virus. Transduced cells were selected by
puromycin treatment. 1 × 106 cells per sample were harvested,
washed in 3 ml ice-cold PBS, fixed in 500 µl PBS with 1%
paraformaldehyde and analyzed using BD Fortessa cell analyzer
for GFP (AF 488, Franklin Lakes, NJ, United States). Samples
were labeled with HIF-1α (BD Biosciences, #610959), PHD2
(Novus Biologicals, #NB100-137, Littleton, CO, United States)
and β actin (Sigma-Aldrich, #A228) antibodies. Treatment of
cells with Fe (III) Citrate and immunoblot assays follows as
described previously (Miles et al., 2017). Experiments were
carried out twice each.
Statistical Analysis
All experiments were performed in triplicate, unless otherwise
stated. OKR data was analyzed using either One-way ANOVA
with Dunnett’s multiple comparisons or Student’s Unpaired
T-test in GraphPad Prism 7/8 (La Jolla, CA, United States). QRT-
PCR data was analyzed using One-way ANOVA with Dunnett’s
multiple comparisons (GraphPad Prism 7) with p ≤ 0.05
considered statistically significant. Rodent explant study values
in all graphs represent the mean ± standard error of the mean
(SEM). Data were statistically analyzed using One-way ANOVA
with Dunnett’s multiple comparisons (GraphPad Prism 8) with
values of p ≤ 0.05 being considered statistically significant.
RESULTS
Selective HDAC6 Inhibitors Significantly
Restore Cone Photoreceptor Vision in
atp6v0e1−/− Zebrafish Model of Retinal
Blindness
The ability of small molecule HDAC6 inhibitors (TubA,
tubacin, ACY-1215 and NF2373) to restore cone photoreceptor
vision was evaluated in atp6v0e1−/− zebrafish larvae, a
genetic model of blindness potentially relevant to IRD and
AMD (Figure 1A). The maximum tolerated concentration
was determined for each HDAC6i, based on the highest
concentration exhibiting no adverse effects on gross morphology
of ≥ 80% surviving larvae and the average optokinetic response
at 5 days post fertilization (dpf) not reduced by more
than 15% (Supplementary Figure S1). atp6v0e1−/− larvae
were treated with these maximum tolerated concentrations
from 3–6 dpf. All HDAC6i tested, improved atp6v0e1−/−
visual function. In hierarchical order, visual behavior improved
significantly with 100 µM TubA and 10 µM Tubacin treatment
producing 7.9 and 4.6 saccades/minute (saccades/min) on
average, respectively, compared to 1.1 saccades/min with vehicle
control treated atp6v0e1−/− larvae (Figure 1B; Supplementary
Figure S2A). A modest, non-significant increase following
10 µM ACY-1215 (2.6 saccades/min on average) or 25 µM
NF2373 (2.3 saccades/min on average) treatment was observed.
Treatment with TubA resulted in the highest magnitude
rescue of visual function with an average 8-fold increase in
saccades. Thereafter, TubA was utilized as a prototypical HDAC6i
for subsequent studies. The duration of atp6v0e1−/− rescue
was determined to understand the time frame of sustained
neuroprotection. atp6v0e1−/− larvae were treated from 3 dpf
with changes to the drug solution once every 3 days. The studies
were stopped at 8 dpf as feeding could not be sustained while
on experiment. A progressive increase in visual function was
observed in 100 µM TubA-treated atp6v0e1−/− culminating
in an average of 7.9 and 17.4 saccades/min at 6 and 7 dpf,
respectively (Figure 1C). Compared to 7 dpf, a non-significant
reduction to 13.5 saccades/min was observed at 8 dpf in
100 µM TubA-treated atp6v0e1 mutants (Figure 1C). There
was no significant difference in the average number of saccades
between vehicle-control or TubA-treated siblings at 6, 7 or
8 dpf (Supplementary Figure S2B). A significant difference
(p-value ≤ 0.0001) in the average number of saccades was
observed at 6 dpf between 100 µM TubA-treated siblings
(17.3 saccades/min) and atp6v0e1 mutants (7.9 saccades/min)
demonstrating that TubA significantly improved vision of
atp6v0e1 mutants, but not to wildtype levels (Figure 1C and
Supplementary Figure S2B). Interestingly, at 7 and 8 dpf,
there was no significant difference in the average number
of saccades between TubA-treated atp6v0e1−/− and siblings
(16.5 saccades/min and 16.3 saccades/min at 7 and 8 dpf,
respectively), highlighting the vast improvement in visual
capacity in TubA-treated atp6v0e1 mutants at these time points
(Figure 1C and Supplementary Figure S2B). Following TubA
treatment, approximately 26% of TubA-treated larvae inflated
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TABLE 1 | Bioinformatic analysis of selected sgRNA guides for specificity and off-targets.
Specificity Score Off-target counts* Predicted efficiency
Oligos Target Sequence MIT CFD Doench ’16-Score
ATP6V0E1 gRNA1 GCGGCGACCATGGCGTATCACGG 93 98 0-0-1-1-9 51
ATP6V0E1 gRNA2 AGTGAGGCCGTGATACGCCATGG 98 96 0-0-0-0-42 62
ATP6V0E1 gRNA3 TCACAATGAGAGGCACAGTGAGG 58 76 0-0-4-28-232 74
PHD2 gRNA ATGCCGTGCTTGTTCATGCACGG 83 93 0-0-0-4-83 62
*An off-target count of “0-0-1-1-9” means that the target matches 0 locations in the genome with 0 or 1 mismatch. There is 1 location with 2 or 3 mismatches each and
9 regions with 4 mismatches.
their swim bladders compared to 100% uninflated swim bladders
in vehicle-control atp6v0e1−/− larvae; and 100 µM TubA-
treated atp6v0e1−/− larvae presented with increased mobility as
shown previously (Leyk et al., 2017). All follow-up studies were
performed with TubA as this HDAC6i treatment elicited the most
efficacious increase in the average number of saccades/min.
HDAC6 Inhibitor Tubastatin A Improves
Retinal Histology and Photoreceptor
Ultrastructure
A significant improvement in vision suggested that TubA
treatment elicits neuroprotective effects on the retina. Thus,
retinal morphology and ultrastructure was analyzed by light
and electron microscopy. Vehicle-control treated atp6v0e1−/− at
6 dpf, had large vacuoles (pink arrows) within the retinal pigment
epithelium (RPE) layer, pyknotic nuclei (red arrows) in the ciliary
marginal zone (CMZ) and aberrantly formed photoreceptor
outer segments (Figure 2Ai). In contrast, we observed that
TubA-treated atp6v0e1−/− displayed improved organization of
the photoreceptor layer, with more elongated outer segments
and decreased CMZ pyknotic nuclei (Figure 2Aii), validating
previous findings (Leyk et al., 2017). TubA improved the
arrangement and packing of long double cones and rods
in the photoreceptor layer (Figures 2B,C; Supplementary
Figure S3). There was no significant increase in the number
of photoreceptors following TubA treatment (Figure 2B). The
total area occupied by photoreceptor outer segments of cones
and rods in TubA-treated atp6v0e1−/− was significantly larger
(p-value = 0.027) compared to atp6v0e1−/− vehicle controls
but not restored to sibling levels (Figure 2C; Supplementary
Figure 4). In summary, the selective HDAC6i, TubA, improved
retinal morphology and photoreceptor ultrastructure consistent
with improved visual behavior.
HDAC6i Tubastatin A Increases Cone
Photoreceptor Survival in rd10 Mouse
Retinal Explants
The capability of TubA to protect against photoreceptor cell
death was determined in an ex vivo mammalian model of
early-stage retinal degeneration, the rd10 mouse at P14. Retinal
explants were prepared from homozygous rd10/rd10 mice
(B6.CXBI−Pde6brd10/J) at postnatal day 14 (P14) as described
previously (Roche et al., 2017, 2018; Ruiz Lopez et al., 2017). At
this stage in vivo, retinal cell types are differentiated and outer
segments elaborated in the murine retina (Bassett and Wallace,
2012). Compared to wildtype retina, a significant reduction in
the length of rod and cone outer segments occurs in rd10
retina between P10 and P15, without a significant reduction
in ONL thickness (Roche et al., 2016). Hence, P14-P18 was
chosen for rd10 explant culture to assess if TubA improved rod
and cone outer segment morphology. Explants were cultured
without the RPE in media containing various concentrations
of TubA or vehicle control (DMSO), with media/drug change
following 2 days in culture and treatment stopped on day
4 of culture (Figure 3A). The RPE supports maturation of
early post-natal retinal explant cultures but is not necessary
in our experimental paradigm as P14 mouse retinae have
already constituted photoreceptor outer segments before culture
(Pinzon-Duarte et al., 2000). Explants were fixed and stained
with cone and rod markers in retinal wholemounts or sections.
The average total number of nuclei in the outer nuclear layer
(ONL) ranged from 44 per field of view (FOV) in vehicle control-
treated explants to 57, 62, 59 and 55 nuclei per FOV in 10, 25, 50
and 100 µM TubA-treated samples, respectively. The observed
changes were not significant (p-value = 0.162) (Figure 3B). The
average number of cells with rhodopsin-positive outer segments
changed from 40 in vehicle control to 39, 41, 43 and 46 cells
in 10, 25, 50 and 100 µM TubA-treated explants, but were
also not significantly (p-value = 0.605) increased (Figure 3B).
Interestingly, 100 µM TubA treatment significantly (adjusted
p-value = 0.024) increased, from an average of 6 in vehicle-
treated controls to 12, the number of cone outer segments
labeled with cone arrestin (Figure 3B). Wholemount analysis
of the explants support the retinal section data, demonstrating
a significant (adjusted p-value = 0.006 and 0.030, respectively)
increase (from 56 to 160 and 137, respectively) in the average
number of cells expressing cone arrestin in 50 and 100 µM
TubA treatment groups (Figure 3C). On the other hand,
no significant (p-value = 0.217) difference in the rhodopsin
fluorescence intensity was observed between vehicle-control and
TubA-treated explants.
ATP6V0E1 Subunit Regulates HIF-1α
Levels Through Iron
Recently, V-ATPase inhibition or depletion of other subunits
of the multi-functional complex were reported as regulators of
HIF-1α levels in a process related to levels of free intracellular
iron (Miles et al., 2017). To quantitatively determine if the
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FIGURE 1 | Selective HDAC6i significantly restores visual function in atp6v0e1−/−, a zebrafish model of retinal blindness. (A) Table describing the physiochemical
properties of the four HDAC6i candidates selected for present study. Chemical structures were drawn using Chemspider (http://www.chemspider.
com/StructureSearch.aspx). (B) atp6v0e1−/− mutants were treated at maximum tolerated concentration (refer to Supplementary Figures S1, S2A) of each
HDAC6i, from 3–6 days post fertilization (dpf). Visual function was markedly improved upon treatment with 100 µM TubA, 10 µM Tubacin, 10 µM ACY-1215 or
25 µM NF2373 compared to vehicle-control (0.1% DMSO) treated larvae. Panel on right shows representative larval wholemount images. Statistical analysis was
performed using One-way ANOVA with Dunnett’s multiple comparisons, where ∗∗∗ p-value = 0.0008 and ∗∗∗∗ means a p-value of ≤ 0.0001. N = 3 and n = 12 per
treatment group. (C) The duration of action of TubA was determined, whereby atp6v0e1−/− larvae were treated from 3 to 8 dpf, and visual function measured at 6,
7 or 8 dpf (refer to Supplementary Figure S2B for visual response in siblings). A significant increase in visual response was recorded at 7 and 8 dpf, respectively.
Representative larval images presented in the right panel. Student’s T test was used for statistical analysis, where ∗∗∗ means a p-value of ≤ 0.0001. N = 3 and
n = 12 per treatment group.
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FIGURE 2 | TubA treatment improved retinal morphology in atp6v0e1−/− larvae. (Ai) LM images revealed large vacuoles (pink arrows) in the RPE layer, pyknotic
nuclei (red arrows) in the CMZ and shortened photoreceptor outer segments in vehicle-control treated atp6v0e1−/− mutants. (Aii) The photoreceptor outer
segments were observed to be more elongated, more prominent, and better organized in TubA-treated atp6v0e1−/− mutants compared to vehicle-control treated
atp6v0e1−/− mutants (Supplementary Figure S3). (B,C) Confocal images of immuno-stained vehicle-control or TubA-treated atp6v0e1−/− mutant retina with
cone (zpr-1) photoreceptor and rod and cone outer segment (zpr-3) specific markers. (Bi,Ci) Panels present aberrant cone and rod outer segment morphology in
vehicle-control treated atp6v0e1−/− mutants. (Bii,Cii) TubA treatment improved photoreceptor structural integrity and organization in atp6v0e1−/− mutants.
(Biii,Ciii) Graphical presentation of the number of cone cells (zpr-1 staining) and total area occupied by photoreceptor outer segments (zpr-3 staining), respectively
(refer to Supplementary Figure S4 for analysis of retinal histology in siblings; 3 sections per sample was analyzed, N = 3). Student’s unpaired T-test was used for
statistical analysis.
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FIGURE 3 | TubA preserves cone cells in rd10 mice retinal explants. (A) Schematic diagram outlining the drug treatment protocol in retinal explants from
homozygous rd10/rd10 mice (B6.CXBI–Pde6brd10/J) at postnatal day 14 (P14). (B) Retinal section fluorescent images of explants treated with increasing
concentrations of TubA or vehicle control, labeled for rhodopsin (rods) and cone arrestin (cones). The total number of nuclei in the outer nuclear layer (ONL) did not
change significantly across the TubA treatment group. Likewise, the number of rhodopsin positive outer segments did not significantly change. A dose-dependent
increase in the number of cone arrestin positive outer segments was observed, with a significant increase following 100 µM TubA treatment. (C) In wholemount
preparations, no significant increase in fluorescence intensity of rhodopsin positive cells, was observed following TubA treatment. A significant increase in the number
of cells with cone arrestin positive outer segments was identified at 50 µM and 100 µM TubA treatment. Statistical analysis was performed using One-way ANOVA
with Dunnett’s multiple comparisons. N = 4 per treatment group.
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human ATP6V0E1 subunit ortholog regulated HIF-1α activity,
comparable to other V-ATPase subunits, we used the dynamic
HIF-1α fluorescent reporter (HeLa HRE-GFPODD cells) cell
line, as described previously (Burr et al., 2016). The HeLa
HRE-GFPODD cell line was selected for this experiment as
the cell line has validated, bespoke modifications incorporating
a HIF-1α driven reporter transgene allowing for quantitative
analysis of HIF-1α activity and direct comparison of the role
of the ATP6V0E1 subunit with other V-ATPase subunits in
the same cell line. As expected, pharmacological inhibition of
the V-ATPase complex with 10 nM bafilomycin A1 (BafA) led
to a significant increase in HIF1α-GFPODD reporter activity
in HeLa cells, 98.2% HIF1α-GFP positive cells compared to
1.4% in untreated controls (Figures 4A,B). Co-supplementing
cells treated with 10 nM BafA and 100 µM of Fe (III)
citrate, significantly reduced HIF1α-GFP positive cells to 1.77%,
consistent with HIF-1α stability being dependent on intracellular
iron abundance. We then investigated if the human ATP6V0E1
ortholog regulates HIF-1α levels. Lentiviral knock-down of
ATP6V0E1 with three CRISPR-Cas9 guides was performed
resulting in increased HIF-1α activity (42.0%, 82.3% and 51.5%,
respectively, with atp6v0e1 guides 1, 2 and 3) as measured by
HIF1α-GFPODD reporter activity in HeLa cells (Figure 4C). This
effect was reversed (HIF-1α levels were reduced to 4.58, 55.5,
and 29.8%, respectively) by co-treatment with 100 µM Fe (III)
citrate (Figure 4C). PHD2 depleted cells were used as a negative
control, whereby knock-down of PHD2 resulted in a significantly
higher number of HIF1α-GFP positive (86.7%) cells and, as
expected, treatment with 100 µM Fe (III) citrate did not reduce
the number of HIF1α-GFP positive (85.2%) cells (Figure 4C).
Immunoblotting confirmed that Fe (III) citrate treatment reduces
HIF-1α levels in BafA treated cells and ATP6V0E1 depleted cells
(Figure 4D). However, Fe (III) citrate does not alter HIF-1α levels
in PHD2 depleted cells. This data revealed that the ATP6V0E1
subunit functionally regulates HIF-1α levels in vitro.
HDAC6 Inhibitor Tubastatin A Does Not
Modulate hif-1α Target Transcripts in
atp6v0e1−/− Eyes at 3 or 6 dpf
Whole genome sequencing was performed to define the genetic
deletion in atp6v0e1−/− larvae. Bioinformatic analysis identified
an approximately 4,098 base pair deletion, spanning from exon
2 to the 3′ UTR region of atp6v0e1 (Figure 5A). Previously,
we reported atp6v0e1−/− results from a 180 base pair deletion,
but this was due to a spurious transcript arising from PCR
amplification (Daly et al., 2017). The large deletion identified by
genome sequencing is predicted to introduce a premature stop
codon and induce nonsense mediated transcript decay. atp6v0e1
transcripts are significantly reduced in atp6v0e1−/− compared to
siblings (unpublished data).
We hypothesized that lack of a functional atp6v0e1 will result
in elevated Hif-1α levels, in vivo. To link with our earlier
finding that Fe (III) citrate normalizes HIF-1α reporter activity,
upregulated in vitro by ATP6V0E1 depletion, we co-treated
atp6v0e1−/− zebrafish with 100 µM Fe (III) citrate, 100 µM
ascorbic acid and 1 mg/ml of lactoferrin from 3–6 dpf, replacing
drug solutions daily. Supplementing iron failed to significantly
rescue atp6v0e1−/− visual function at 6 dpf (Figure 5B). Average
saccades/min of 0.7 or 1.1 saccades/min were obtained in vehicle-
control or iron supplemented atp6v0e1−/− larvae, respectively.
To test the related theory that an upregulation of HIF-
1α arises in atp6v0e1−/− zebrafish eyes and contributes to
retinal blindness, the transcript levels of hif1aa and hif1aa
target genes (ca9, slc2a1a and vhl) were quantified by qRT-
PCR at two time-points. Treatment started at 3 dpf and RNA
was extracted from vehicle-control or TubA-treated eyes at 4 h
post treatment (hpt) or 3 days post-treatment (dpt). In vehicle-
control treated atp6v0e1−/− larvae compared to siblings, there
was no significant transcript increase in hif1aa or hif1aa target
genes (ca9, slc2a1a and vhl) at 4 hpt (Figure 6A). But hif1aa
(2.3 fold; adjusted p-value ≤ 0.0001) and the hif1aa target
genes (ca9, slc2a1a and vhl; 2.3, 3.4 and 3.1 fold, respectively;
adjusted p-value ≤ 0.0001, 0.0168 and 0.0241, respectively) were
significantly downregulated at 3 dpt (i.e., 6 dpf) (Figure 6B). We
then investigated if HDAC6i treatment alters HIF-1α signaling.
However, treatment with 100 µM TubA did not significantly
alter hif1aa or the hif1aa target genes (ca9, slc2a1a and vhl) in
atp6v0e1−/− at 4 hpt or 3 dpt (Figures 6A,B). Three markers of
retinal differentiation, gnat2, opn1lw2 and rx2 were also analyzed.
A significant increase (1.4 fold; adjusted p-value = 0.0275) in rx2
transcripts were observed in atp6v0e1−/− larvae compared to
vehicle-control treated siblings at 4 hpt (Figure 6A). Treatment
with 100 µM TubA did not significantly change gnat2, opn1lw2
and rx2 levels at 4 hpt. In contrast, all three genes were
significantly downregulated (gnat2, opn1lw2 and rx2; 4.0, 3.0
and 3.5 fold, respectively; adjusted p-value = 0.0003, 0.0016,
and 0.0113, respectively) in atp6v0e1−/− at 3 dpt (Figure 6B).
A significant increase (2.0 fold; adjusted p-value = 0.0346) in
opn1lw2 but not gnat2 or rx2 was observed in atp6v0e1−/− after
HDAC6i treatment.
In summary, there is no evidence that loss of atp6v0e1 in vivo
alters Hif-1α signaling or phototransduction gene expression
in 3 dpf eyes, with or without HDAC6i treatment. However,
at 6 dpf, zebrafish knock-outs of atp6v0e1 display significantly
reduced levels of transcripts for Hif-1α and phototransduction
signaling genes. HDAC6i treatment from 3–6 dpf is sufficient
to significantly increase transcript levels of the red-sensitive
opsin gene (opn1lw2) in atp6v0e1−/−larvae, consistent with the
improved retinal histology and visual behavior.
Proteome Profiling Revealed That
Tubastatin A Modulates Several Cellular
Processes to Mediate the Observed
Rescue of Vision
As an unbiased approach to understand ocular disease
mechanisms associated with atp6v0e1−/− and therapeutic
mechanisms associated with HDAC6 inhibition, proteome
profiling was performed. In 6 dpf eyes, a total of 4611
proteins were identified following liquid chromatography
mass spectrometry analysis. 790 proteins were statistically
altered, out of which 119 ocular proteins were significantly
upregulated and 50 downregulated when a cut-off of ± 1.2
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FIGURE 4 | Iron supplementation restores HIF-1α levels to normal following ATP6V0E1 inhibition in HeLa cells. (A) Schematic diagram of the multimeric V-ATPase
complex. (B) Chemical inhibition of V-ATPase by 10 nM BafA treatment for 24 h, increased HIF-1α levels in HIFα-GFPODD reporter cells. Treatment with 100 µM Fe
(III) citrate significantly reduced the elevated HIF-1α levels associated with loss of ATP6V0E1 (1 × 106 cells per sample harvested and analyzed; N = 2).
(C) Knock-down of ATP6V0E1 subunit with three different CRISPR-Cas9 guides resulted in significant upregulation of HIF-1α levels in HIFα-GFPODD reporter cells.
Co-treating cells with 100 µM Fe (III) citrate led to a reduction in HIF-1α levels across the three ATP6V0E1 depleted cells. phd2 was knocked down as a control and
treatment with 100 µM Fe (III) citrate did not result in reduction of HIF-1α levels (1 × 106 cells per sample harvested and analyzed; N = 2). FACs plot shown is a
representative image of two biological repeats performed. (D) Immunoblot analysis for HIF-1α and PHD2 levels in HIFα-GFPODD reporter cells with either ATP6V0E1
or PHD2 depleted or treated with 10 nM BafA. The cells were treated with 100 µM Fe (III) citrate for 24 h. β actin was used as a control. Results validated findings
observed by flow cytometry, whereby HIF-1α levels were upregulated following ATP6V0E1 knock-down or inhibition and levels were re-normalized upon Fe (III) citrate
treatment. Treatment of Fe (III) citrate in PHD2 depleted cells did not alter HIF-1α levels. All experiments were performed in biological duplicate.
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FIGURE 5 | Iron supplementation did not restore vision in atp6v0e1 mutants. (A) Schematic diagram depicting the 4,098 bp deletion in the atp6v0e1 subunit
identified through whole genome sequencing. (B) Treatment of atp6v0e1−/− with 100 µM Fe (III) citrate, co-supplemented with 100 µM ascorbic acid and 1 mg/ml
of lactoferrin daily for 3 days, did not restore visual function as measured by OKR. Experiments were performed in duplicate and Student’s T-Test was used for
statistical analysis.
fold change and − log p-value ≥ 1.3 was applied, between
siblings and atp6v0e1−/− knock-outs, as presented by volcano
plot and heatmap (Figures 7A,B). The most downregulated
ocular proteins in atp6v0e1−/− include regulators of the
vitamin A/retinoid cycle (retinol binding protein 3, retinol
dehydrogenase 20) and metabolism (facilitated glucose
transporter 1) (Figure 7C). The most upregulated ocular
proteins in atp6v0e1−/− include proteins involved in antioxidant
activity, estrogen signaling (vitellogenin 1, 6 and 2), muscle
movement (myosin, heavy polypeptide 1.1, skeletal muscle and
myosin, heavy chain b) and lipid metabolism (apolipoprotein
Bb and apolipoprotein Ea) (Figure 7C). To probe deeper,
we analyzed differentially expressed pathways or cellular
processes linked with disease pathogenesis in atp6v0e1−/−
larvae. KEGG pathway analysis of all differentially expressed
proteins identified proteins involved in phototransduction
(e.g., Rho, Gnat1, Gnat2, Gngt1, Grk1b, Rcvrn2, Rgs9a and
Saga), phagocytosis (e.g., Atp6ap1a, Atp6v0d1, Atp6v1c1a,
Atp6v1g1, Atp6v1h, Aalr3a, Tubb6, Tuba2 and Vamp3), arginine
biosynthesis (e.g., Glsa, Got1, Got2a and Otc), arginine and
proline metabolism (e.g., Ckbb, Ckmt1, Ckmt2a, Got2a and Oat),
glycolysis/gluconeogenesis (e.g., Aldoaa, Eno1b, Eno2, Pgam1b
and Pkma), fructose and mannose metabolism (e.g., Aldoaa,
Aldocb, Pfkpa, Pfkpb) and pentose phosphate pathway (e.g.,
Aldocb, Pfkpb, Pgm2 and Tkta), as significantly downregulated
in atp6v0e1−/− (Figure 7D). Protein processing in endoplasmic
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FIGURE 6 | Analysis of hif1aa and targets expression levels in atp6v0e1−/− treated with TubA. (A) hif1aa and select hif1aa downstream target gene(s) expression
levels were quantified by qRT-PCR at 4 hpt (i.e., at 3 dpf). No significant changes in hif1aa, slc2a1a, vhl or ca9 transcript levels occurred in atp6v0e1−/− in
comparison to vehicle-control treated siblings. Treatment with TubA did not significantly alter these transcript levels either. In atp6v0e1−/−, retinal-specific genes
gnat2 and opn1lw2 were not significantly changed but rx2 was significantly upregulated. Upon treatment with TubA, no significant reduction in rx2 transcript levels
was detected. (B) Similarly, hif1aa and select hif1aa downstream target gene(s) expression levels were quantified at 3 dpt (i.e., at 6 dpf). A significant reduction in
hif1aa, ca9, slc2a1a and vhl transcript levels was identified in vehicle-control treated atp6v0e1−/−. Retinal-specific genes gnat2, opn1lw2 and rx2 were also
significantly downregulated compared to vehicle-control treated siblings. TubA-treatment of atp6v0e1−/− resulted in no significant change in hif1aa, ca9, slc2a1a
and vhl levels. opn1lw2 transcript levels were significantly increased following TubA-treatment. All experiments were performed in triplicates (n = 60 eyes/treatment
condition) and one-way ANOVA with Dunnett’s multiple comparisons was used for statistical analysis.
reticulum (e.g., Calr3b, Ddost, Hsp70.3, Hsp90ab1, Hsp90b1,
Hyou1, Rrbp1a and Sec23a), ECM-receptor interaction (e.g.,
Col2a1a, Col9a3, Lamc1, Thbs1b, Tnc and Vtnb) and focal
adhesion (e.g., Actn1, Col2a1a, Ilk, Lamc1, Myl12.1, Thbs1b, Tnc
and Vtnb) pathways were upregulated (Figure 7D).
Similarly, we analyzed the most differentially expressed
proteins in atp6v0e1−/− after HDAC6i treatment. Given a cut-off
of ± 1.2, and a −log p-value of ≥ 1.3, 23 and 50 proteins were
up or downregulated, respectively, out of 347 proteins that were
identified to be statistically changed (Figures 8A,B). The most
downregulated ocular proteins in TubA-treated atp6v0e1−/−
include retinoblastoma binding protein 9, tubulin alpha chain
and myosin regulatory light chain 2 (Figure 8C). The most
upregulated ocular proteins in HDAC6i treated atp6v0e1−/−
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FIGURE 7 | Continued
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FIGURE 7 | Multiple pathways are implicated in the disease pathomechanism of atp6v0e1−/− as identified by proteome profiling. (A,B) Volcano plot and heatmap
representing 790 differentially expressed proteins between vehicle-control treated siblings and atp6v0e1−/−, out of which, 119 proteins were upregulated (in red)
and 50 downregulated (in blue) significantly, given a cut-off of fold change ± 1.2 and –log p-value ≥ 1.3. Student’s T-Test was used for statistical analysis. (C) Table
describing the top-most significantly downregulated and upregulated proteins. (D) KEGG pathway analysis of significantly downregulated and upregulated proteins
in vehicle-control treated atp6v0e1−/− compared to vehicle-control treated siblings.
include Glutaryl-CoA dehydrogenase, 28S ribosomal protein,
microtubule-associated protein(s) and Triokinase/FMN cyclase.
Pathway analysis identified the most enriched GO terms as
phototransduction (e.g., Grk7a, Grk7b, Rcvrn2 and Rgs9a),
cardiac muscle contraction (e.g., Atp1a3a, Atp1b2a, Atp1b4 and
Cox5ab), endocytosis (e.g., Arr3a, Ehd3, Grk7a, Grk7b, Kif5bb,
Snx3 and Vps29), proteasome (e.g., Psmc4, Psmd11b and Si:rp71-
45k5.4) and gap junction (e.g., Csnk1da, Prkacaa, Prkcaa and
Zgc:65894). Interestingly, proteins involved in metabolism such
as arginine biosynthesis (e.g., Ass1, Glsa, Glulb and Got1),
arginine and proline metabolism (e.g., Ckbb, Ckmt2a, Got1,
Oat), alanine, aspartate and glutamate metabolism (e.g., Ass1,
Glsa, Glulb and Got1) and glycolysis/gluconeogenesis (e.g.,
Aldoaa, Eno2, Eno3 and Pkma) were significantly upregulated
(Figure 8D). ECM-receptor interaction (e.g., Col1a2, Col2a1a,
Col9a2 and Lamc1) was downregulated, and phagosome pathway
(e.g., Atp6v0d1, Calr3a, Stx12, Tuba4l, and Zgc:65894) was
moderately altered (Figure 8D). From the pathway analysis, it
was evident that cellular processes such as phototransduction,
metabolism and phagocytosis that were dysregulated in the
atp6v0e1−/− eyes, were positively restored and proteasome and
endocytosis pathways were increased upon HDAC6i treatment.
DISCUSSION
Here, we report that selective inhibitors of HDAC6 restore
functional cone photoreceptor vision in a zebrafish model of
blindness arising from deletion of the atp6v0e1 subunit of
V-ATPase and restore cone photoreceptor survival in a mouse
IRD model arising from a missense mutation of the catalytic
phosphodiesterase 6B subunit. The finding that HDAC6i can
primarily preserve cone function/cells in these diverse animal
models is intriguing, given that zebrafish predominantly uses
cone mediated color vision while mice have rod-dominant vision
(Bibliowicz et al., 2011; Huberman and Niell, 2011). Additionally,
the positive effects observed in our in vivo zebrafish model and
ex vivo rodent model are indicative that HDAC6i may be of
clinical relevance, an opportunity that needs to be explored.
The beneficial effect of HDAC6 inhibition on cone
photoreceptors in the zebrafish atp6v0e1−/− and rd10 mouse
models indicates some common mechanisms of disease. One
candidate is elevated HIF-1α signaling, a hallmark of IRD and
AMD arising from hypoxia within the eye (Lange et al., 2011;
Trachsel-Moncho et al., 2018). Reassuringly, elevated HIF-1α
protein levels in retinae of rd10 mice was previously reported
(Wang et al., 2014). A more recent publication, reported a cyclical
pattern of retinal HIF-1α expression in rd10 retinae, wherein
expression was lower than wildtypes but increased Hif-1α
levels correlated with two phases of photoreceptor degeneration
(Olivares-Gonzalez et al., 2018). In relation to atp6v0e1, genetic
knock-down of other V-ATPase subunits resulted in increased
Hif-1α levels in vitro (Miles et al., 2017). Our research reveals
CRISPR-Cas9 knock-down of the ATP6V0E1 subunit in Hela
cells is sufficient to increase Hif-1α levels, an effect mimicked
by pharmacological (BafA) inhibition of the V-ATPase complex.
However, in vivo, hif1aa and its targets (ca9, slc2a1a and vhl)
were not significantly upregulated in atp6v0e1−/− eyes at
3 dpf and were significantly downregulated at 6 dpf. Overall,
our data does not rule out an in vivo pathological role for
HIF-1α signaling in atp6v0e1−/−; it appears there is a potential
oscillating pattern akin to rd10 mice and cell-specific Hif-1α
alterations are potentially masked by analysis performed on
whole eyes. We considered whether HDAC6 inhibition could be
mediating beneficial effects by modulating HIF-1 signaling in the
retinae. Evidence in support is that HDAC6 promotes HIF-1α
transcriptional activity in vitro, a unique feature of this Class
IIb HDAC, and contrasting with Class I and IIa HDACs which
increase HIF-1α stability (Chen and Sang, 2011; Schoepflin
et al., 2016). Furthermore, inhibition of HDAC6 in Vhl−/−
human renal carcinoma cells led to reduced HIF-1α expression
and activity (Qian et al., 2006). Here, in vivo, Tubastatin A
treatment did not significantly modulate transcript levels of
hif1aa or selected downstream targets in atp6v0e1−/− retinae,
albeit cell-specific changes may be masked. Additionally, we
show that elevated levels of Hif-1α levels upon knock-down of
the ATP6V0E1 subunit, are regulated by iron supplementation
in HeLa cells. In vivo, in the atp6v0e1−/− larvae under our
treatment regime, we did not observe an improvement in visual
function. However, this could be attributed to multiple caveats
involved in our iron treatment regime in zebrafish, e.g. inability
to quantify iron levels absorbed by the larvae or intracellular iron
levels in the retinae to ensure that sufficient iron was delivered
to the eyes to be effective. Furthermore, the timepoint at which
iron is supplemented and the treatment duration needs to be
optimized, given that there could potentially be a modulation
of hif1aa levels over time. Therefore, we cannot rule out the
possible role of iron regulating retinal hif1aa levels in vivo, and
future experiments need to address these limitations.
An alternative common mechanism of disease in zebrafish
atp6v0e1−/− and mouse rd10 models is altered autophagy,
a survival pathway responding to cellular stress (Moreno
et al., 2018). The V-ATPase is a key component of autophagy;
its proton pumping activity allows activation of lysosomal
acid hydrolases which degrade cargo from autophagosomes
(Mijaljica et al., 2011). Although PDE6 does not directly
regulate autophagy, previous reports document increased levels
of autophagy in rd10 retinae (Rodriguez-Muela et al., 2015;
Trachsel-Moncho et al., 2018). We questioned if HDAC6
inhibition could modulate altered processes related to autophagy
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FIGURE 8 | TubA plays a multifaceted role to improve visual function and preserve photoreceptors. (A,B) A total of 347 proteins were identified to be differentially
expressed between 3–6 dpf vehicle-control and TubA-treated atp6v0e1−/−. 23 proteins were upregulated (red) and 50 proteins downregulated (blue), with a cut-off
of fold change ± 1.2 and –log p-value ≥ 1.3, as shown by the volcano plot and heatmap. Student’s T-Test was used for statistical analysis. (C) Table listing the most
significantly down- and upregulated proteins. (D) Graphical representation of significantly downregulated and upregulated pathways in TubA-treated atp6v0e1−/− as
identified by KEGG pathway analysis.
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in atp6v0e1−/− or rd10 retinae. In iPSC-derived RPE cells,
the pan-HDAC inhibitor valproic acid restored outer segment
phagocytosis levels which were blocked by the V-ATPase
inhibitor bafilomycin-A1 (Singh et al., 2015). Here, proteomic
profiling of atp6v0e1−/− eyes shows moderately reduced levels of
phagosome proteins compared to wildtype siblings, and HDAC6
inhibition resulted in moderately increased levels of phagosome
proteins in atp6v0e1−/− eyes.
Collectively, there is reason to consider HIF-1 signaling and
autophagy as therapeutic targets of HDAC6i for atp6v0e1−/−
or rd10 related blindness, but with potential applicability to a
wider cohort of IRD and AMD patients. However, caution must
be exercised as there is controversy regarding both pathways.
Several studies show attenuating Hif-1α signaling has beneficial
effects for photoreceptor-related blindness. Conditional knock-
out of Vhl in mouse rod photoreceptors, led to increased Hif-1α
levels; an anti-Hif1α shRNA protected cells from the associated
photoreceptor degeneration (Barben et al., 2018a). Moreover,
in a mouse model mimicking AMD pathogenesis, inhibiting
Vhl and Hif1α prevented cone photoreceptor degeneration and
abnormal vessel growth (Barben et al., 2018b). However, in
contrast, others report that stabilizing HIF-1 signaling prevents
retinal degeneration. Stabilization of Hif-1α protected against
photoreceptor cell death in pre-clinical models of retinal
detachment and retinopathy of prematurity (Hoppe et al.,
2016; Liu et al., 2016; Cheng et al., 2017). Indeed, in rd10
mice, pharmacologically inhibiting HIF-1α degradation with
dimethyloxalylglycine (DMOG) prevented photoreceptor loss
(Olivares-Gonzalez et al., 2018). In relation to autophagy,
conditional knock-out of Atg5 (autophagy gene involved in the
formation of autophagosomes) in murine rod photoreceptors
resulted in the accumulation of visual transduction proteins and
consequent degeneration of photoreceptors (Yao et al., 2016).
In rd10 mice, promoting autophagy with rapamycin, increased
retinal cell death (Rodriguez-Muela et al., 2015). However, other
studies report autophagy is increased as a mechanism to clear out
mutant proteins or damaged cells or as a response to oxidative
stress (Kaushal, 2006; Kunchithapautham and Rohrer, 2007;
Bogea et al., 2015). Hence, a balance is required in autophagy in
diseased conditions to ensure a beneficial effect (Moreno et al.,
2018; Lin and Xu, 2019).
In addition to these candidate disease pathways, unbiased
proteomic profiling identified phototransduction and metabolic
pathways, linked with HDAC6i rescue of atp6v0e1−/−. However,
these pathways can be viewed from different perspectives,
either as a cause or consequence. In vehicle-control treated
atp6v0e1−/−, proteins in the phototransduction pathway were
downregulated, which implies that either there is a lack
of phototransduction related proteins (cause) leading to the
reduced visual function (consequence) or that the aberrant
morphology/degenerating photoreceptors (cause) resulted in
the reduced expression of retinal protein leading to vision
loss (consequence). Reassuringly, phototransduction-specific
proteins were upregulated upon TubA treatment which supports
the observed increase in functional vision. This could mean
either (1) TubA is neuroprotective of retinal cells (cause),
leading to increased protein levels and activity (consequence)
or (2) the increase in expression of phototransduction proteins
(cause) supports the observed preservation and activity of
photoreceptors (consequence) in the retina. We additionally
analyzed expression levels of select inner retinal proteins (i.e.,
Slc6a9, Calb2a, Calb2b, Snap25a, Prkca and Vim) and found
that these proteins were not altered in atp6v0e1 mutants. This
further supports the notion that defects in photoreceptors are
causative of the compromised visual function in the mutants and
our findings need to be further investigated in follow up studies.
Interestingly, TubA increased expression levels of metabolic
proteins involved in arginine biosynthesis, alanine, aspartate
and glutamate metabolism and glycolysis/gluconeogenesis in
atp6v0e1 mutants. Functional vision is an energy-demanding
process and photoreceptors are known to utilize glucose
primarily as their energy source (Narayan et al., 2017). The
observed increase in metabolic processes may correlate to
improved energy consumption of functional retinal cells in
atp6v0e1−/− following HDAC6 inhibition. Several proteins
involved in a variety of metabolic pathways were downregulated
in vehicle-control treated atp6v0e1−/−. This could mean
either (1) there was an insufficient amount of energy sources
(cause) in the retina leading to non/reduced retinal functions
(consequence) or (2) the reduction in proteins related to
metabolic pathway(s) observed (consequence) is due to the
reduced visual function of retinal cells (cause). Likewise, the
observed increase in levels of metabolic proteins following
treatment with TubA indicates that either (1) TubA increased
the levels of proteins responsible for providing energy sources
(cause) in the retina leading to increased retinal functions
(consequence) or (2) as there is increased retinal function, due
to the preservation of retinal cells (cause), there is an increase
in energy consumption (consequence) by the retinal cells. As the
pathways identified from our study, could be addressed as either
the cause or consequence, we are proposing that HDAC6i plays
a multifaceted role in ensuring the preservation and function
of retinal cells. This highlights the need to identify and validate
driver pathways mediating restoration of vision through HDAC6i
by profiling changes at earlier time points.
In summary, our data provides evidence that HDAC6i
are efficacious as photoreceptor neuroprotectants whose
potential as a therapeutic option for retinal and macular
degenerations warrants further investigation. Indeed, as loss
of cone photoreceptor vision is associated with the most
detrimental impact on vision in IRD and AMD, our findings
suggest HDAC6 inhibitors and associated target pathways
offer potential treatments to patients affected by these blinding
conditions. Important questions to address in the future are the
safety and efficacy profile of HDAC6i, evaluation of the impact of
HDAC6i treatment on long term visual function and intraocular
delivery of HDAC6i in rodent models, in vivo, to fully appreciate
the therapeutic potential of HDAC6i for treatment of IRD and
AMD. As HDAC6i are selective and act on non-histone proteins,
side effects associated with pan-HDACi are less concerning.
With over 270 genes causative of IRD, HDAC6 inhibition offers
potential for a wider subset of patients than single gene therapies.
However, both the disease mechanisms and the stage of disease
must be taken into consideration.
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